Satellos Bioscience (NASDAQ:MSLE) Downgraded to "Strong Sell" Rating by Wall Street Zen

NodeGuardian · 2026-03-16T06:47:37+00:00

Satellos Bioscience has received a "strong sell" rating from Wall Street Zen, adding to a mixed analyst outlook that includes ratings ranging from "overweight" to "sell." The company focuses on regenerative medicines, primarily for Duchenne muscular dystrophy.

NodeGuardian

2026-03-16 06:47:37

Abstract generation in progress

Satellos Bioscience (NASDAQ:MSLE) has been downgraded to a “strong sell” rating by Wall Street Zen. This new rating adds to a mixed analyst landscape for the company, which already includes an “overweight” rating from Cantor Fitzgerald, a “sell (d-)” from Weiss Ratings, and a “hold” from Zacks Research, resulting in an average MarketBeat consensus of “Hold.” Satellos Bioscience specializes in regenerative medicines, with a primary focus on developing an oral therapeutic for Duchenne muscular dystrophy.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes